Sandoz Group (OTCMKTS:SDZNY) Stock Price Down 0.9% - Should You Sell?

Key Points

• Sandoz Group's stock price decreased by 0.9%, closing at $56.78 after trading as low as $56.10.
• The Royal Bank of Canada upgraded Sandoz Group’s rating from "hold" to "moderate buy," indicating a positive shift in analyst sentiment.
• Sandoz Group specializes in developing and marketing generic pharmaceuticals and biosimilars across multiple therapeutic areas, including oncology and infectious diseases.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report)'s share price was down 0.9% during mid-day trading on Tuesday . The company traded as low as $56.10 and last traded at $56.78. Approximately 20,913 shares were traded during trading, a decline of 4% from the average daily volume of 21,781 shares. The stock had previously closed at $57.31.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada upgraded shares of Sandoz Group from a "hold" rating to a "moderate buy" rating in a report on Friday, May 2nd.

Sandoz Group Stock Performance

The company has a current ratio of 1.24, a quick ratio of 0.79 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $55.15 and a 200 day simple moving average of $48.05.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.